- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Next-line ibrutinib
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 16
- States / cities
- Duarte, California • La Jolla, California • Stanford, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 50,386
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
- Drug
- Lead sponsor
- Glenmark Pharmaceuticals Ltd. India
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
- Conditions
- Healthy
- Interventions
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Acne Vulgaris
- Interventions
- Winlevi (clascoterone) 1% & Adapalene 0.3% gel
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands
- Interventions
- Selumetinib, Olaparib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Cenerimod
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Clearwater, Florida • DeBary, Florida + 8 more
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- STRO-002
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Psoriasis Vulgaris
- Interventions
- LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle, LEO 90100 vehicle
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 39
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 30 more
- Conditions
- Alzheimer's Disease
- Interventions
- bapineuzumab, placebo
- Drug · Other
- Lead sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 26
- States / cities
- Sun City, Arizona • Irvine, California • Los Alamitos, California + 23 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- isatuximab SAR650984, lenalidomide, dexamethasone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 5
- States / cities
- San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more
- Conditions
- Ovarian Neoplasms
- Interventions
- Vorinostat
- Drug
- Lead sponsor
- Gynecologic Oncology Associates
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Cancer, Major Depressive Disorder
- Interventions
- Psilocybin, Placebo
- Drug
- Lead sponsor
- Sunstone Medical
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia
- Interventions
- Eltrombopag
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Pembrolizumab, Binimetinib, Oxaliplatin, Leucovorin, 5-Fluorouracil [5-FU], Irinotecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 10
- States / cities
- Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Overweight, Obesity
- Interventions
- LY4167586, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence
- Interventions
- Cannabidiol (CBD) 800 mg, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- North Hollywood, California
- Conditions
- Contraception
- Interventions
- 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
- Drug
- Lead sponsor
- Premier Research
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Denver, Colorado • Lexington, Kentucky + 11 more
- Conditions
- HIV-1-infection
- Interventions
- Lenacapavir, Bictegravir/Lenacapavir (BIC/LEN) FDC, Bictegravir/Lenacapavir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 1 more
- Conditions
- Hepatitis C
- Interventions
- Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
- Other · Biological
- Lead sponsor
- Biolex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
- Conditions
- Breast Cancer, Pharmacokinetics
- Interventions
- SPI-2012
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Fountain Valley, California • Glendora, California + 37 more
- Conditions
- Multiple Myeloma
- Interventions
- Part 1 (Dose Escalation): Daratumumab, Part 2 (Dose Expansion): Daratumumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hemophagocytic Lymphohistiocytosis
- Interventions
- Ruxolitinib, Dexamethasone, Etoposide
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 6 Weeks to 22 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Orange, California • San Francisco, California + 10 more
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more